News | April 14, 2025
Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
The company does not expect this development to have any material impact on the current business operations
The supply of these goods is set to commence within the first quarter of FY26
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Strengthening capabilities in Peptide Therapeutics and CDMO services
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Subscribe To Our Newsletter & Stay Updated
